Review



primary antibodies against osteocalcin  (ABclonal Biotechnology)


Bioz Verified Symbol ABclonal Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    ABclonal Biotechnology primary antibodies against osteocalcin
    Osteoblastic autophagy-related genes were upregulated in mouse OA model (A) Representative images of safranin O/fast green staining (top) and immunofluorescence of LC3 and <t>OCN,</t> DDIT3 and <t>OCN,</t> JUN and OCN, VEGFA and OCN (middle and bottom) co-immunostaining in the tibial subchondral bone of controls and DMM mice. Scale bar = 100 μm. (B) Quantitative analysis of the OARSI score of controls and DMM mice. n = 5 per group. (C–F) Quantitative analysis of the percentage of LC3 + , DDIT3 + , JUN + , and VEGFA + cells in OCN + cells of controls and DMM mice. n = 5 per group. (G) Representative images of safranin O/fast green staining (top) and immunofluorescence of LC3 and OCN, DDIT3 and OCN, JUN and OCN, VEGFA and OCN (middle and bottom) co-immunostaining in the tibial subchondral bone of mice aged 4 and 24 months. Scale bar = 100 μm. (H) Quantitative analysis of the OARSI score of mice aged 4 and 24 months. n = 6 per group. Scale bar = 100 μm. (I–L) Quantitative analysis of the percentage of LC3 + , DDIT3 + , JUN + , VEGFA + cells in OCN + cells of mice aged 4 and 24 months. n = 5 per group. (∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001; ns, p > 0.05).
    Primary Antibodies Against Osteocalcin, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against osteocalcin/product/ABclonal Biotechnology
    Average 90 stars, based on 1 article reviews
    primary antibodies against osteocalcin - by Bioz Stars, 2026-05
    90/100 stars

    Images

    1) Product Images from "Identification of osteoblastic autophagy-related genes for predicting diagnostic markers in osteoarthritis"

    Article Title: Identification of osteoblastic autophagy-related genes for predicting diagnostic markers in osteoarthritis

    Journal: iScience

    doi: 10.1016/j.isci.2024.110130

    Osteoblastic autophagy-related genes were upregulated in mouse OA model (A) Representative images of safranin O/fast green staining (top) and immunofluorescence of LC3 and OCN, DDIT3 and OCN, JUN and OCN, VEGFA and OCN (middle and bottom) co-immunostaining in the tibial subchondral bone of controls and DMM mice. Scale bar = 100 μm. (B) Quantitative analysis of the OARSI score of controls and DMM mice. n = 5 per group. (C–F) Quantitative analysis of the percentage of LC3 + , DDIT3 + , JUN + , and VEGFA + cells in OCN + cells of controls and DMM mice. n = 5 per group. (G) Representative images of safranin O/fast green staining (top) and immunofluorescence of LC3 and OCN, DDIT3 and OCN, JUN and OCN, VEGFA and OCN (middle and bottom) co-immunostaining in the tibial subchondral bone of mice aged 4 and 24 months. Scale bar = 100 μm. (H) Quantitative analysis of the OARSI score of mice aged 4 and 24 months. n = 6 per group. Scale bar = 100 μm. (I–L) Quantitative analysis of the percentage of LC3 + , DDIT3 + , JUN + , VEGFA + cells in OCN + cells of mice aged 4 and 24 months. n = 5 per group. (∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001; ns, p > 0.05).
    Figure Legend Snippet: Osteoblastic autophagy-related genes were upregulated in mouse OA model (A) Representative images of safranin O/fast green staining (top) and immunofluorescence of LC3 and OCN, DDIT3 and OCN, JUN and OCN, VEGFA and OCN (middle and bottom) co-immunostaining in the tibial subchondral bone of controls and DMM mice. Scale bar = 100 μm. (B) Quantitative analysis of the OARSI score of controls and DMM mice. n = 5 per group. (C–F) Quantitative analysis of the percentage of LC3 + , DDIT3 + , JUN + , and VEGFA + cells in OCN + cells of controls and DMM mice. n = 5 per group. (G) Representative images of safranin O/fast green staining (top) and immunofluorescence of LC3 and OCN, DDIT3 and OCN, JUN and OCN, VEGFA and OCN (middle and bottom) co-immunostaining in the tibial subchondral bone of mice aged 4 and 24 months. Scale bar = 100 μm. (H) Quantitative analysis of the OARSI score of mice aged 4 and 24 months. n = 6 per group. Scale bar = 100 μm. (I–L) Quantitative analysis of the percentage of LC3 + , DDIT3 + , JUN + , VEGFA + cells in OCN + cells of mice aged 4 and 24 months. n = 5 per group. (∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001; ns, p > 0.05).

    Techniques Used: Staining, Immunofluorescence, Immunostaining

    Osteoblastic autophagy-related genes were upregulated in OA patients (A) Representative images of safranin O/fast green staining (top) and immunofluorescence of LC3 and OCN, DDIT3 and OCN, JUN and OCN, VEGFA and OCN (middle and bottom) co-immunostaining in the tibial subchondral bone of OA patients. Scale bar = 100 μm. (B) Schematic diagram of tibial plateau tissue: in dotted line is the medial, corresponding to the Late-OA(OA group), and the opposite side is the lateral side which as the Early-OA(control group). (C) Quantitative analysis of the OARSI score of early-OA and late-OA. n = 5 per group. (D, E, F and G) Quantitative analysis of the percentage of LC3 + , DDIT3 + , JUN + , and VEGFA + cells in OCN + cells of early-OA and late-OA. n = 5 per group. (H) Western blot analysis the expression of JUN, DDIT3, VEGFA, LC3, COL1A1, RUNX2, and OCN in knee subchondral bone of OA. (I) Quantification of the expression of JUN, DDIT3, VEGFA, LC3, COL1A1, RUNX2, and OCN in knee subchondral bone of OA. (∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001; ns, p > 0.05).
    Figure Legend Snippet: Osteoblastic autophagy-related genes were upregulated in OA patients (A) Representative images of safranin O/fast green staining (top) and immunofluorescence of LC3 and OCN, DDIT3 and OCN, JUN and OCN, VEGFA and OCN (middle and bottom) co-immunostaining in the tibial subchondral bone of OA patients. Scale bar = 100 μm. (B) Schematic diagram of tibial plateau tissue: in dotted line is the medial, corresponding to the Late-OA(OA group), and the opposite side is the lateral side which as the Early-OA(control group). (C) Quantitative analysis of the OARSI score of early-OA and late-OA. n = 5 per group. (D, E, F and G) Quantitative analysis of the percentage of LC3 + , DDIT3 + , JUN + , and VEGFA + cells in OCN + cells of early-OA and late-OA. n = 5 per group. (H) Western blot analysis the expression of JUN, DDIT3, VEGFA, LC3, COL1A1, RUNX2, and OCN in knee subchondral bone of OA. (I) Quantification of the expression of JUN, DDIT3, VEGFA, LC3, COL1A1, RUNX2, and OCN in knee subchondral bone of OA. (∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001; ns, p > 0.05).

    Techniques Used: Staining, Immunofluorescence, Immunostaining, Control, Western Blot, Expressing


    Figure Legend Snippet:

    Techniques Used: Software



    Similar Products

    94
    Bioss primary antibodies against osteocalcin ocn
    Knockdown of enhancer of zeste homolog 2 inhibits steo/dentinogenic differentiation potential of human apical papillary stem cells. A: Quantitative polymerase chain reaction showed that the expression of enhancer of zeste homolog 2 (EZH2) was inhibited in human apical papillary stem cells (hSCAPs); B: Western blot analysis confirmed the knockdown of EZH2 in hSCAPs; C: Knockdown of EZH2 decreased alkaline phosphatase activity in hSCAPs; D and E: Alizarin red staining and quantitative calcium analysis demonstrated that knockdown of EZH2 inhibited mineralization in hSCAPs; F-H: Quantitative polymerase chain reaction showed that knockdown of EZH2 downregulated mRNA expression levels of bone sialoprotein (F), dentin sialophosphoprotein (G), and <t>osteocalcin</t> (H) in hSCAPs. GAPDH and ACTB was used as the internal controls. Data are presented as the mean ± SD ( n = 3). Statistical analysis was performed using Student’s t -test. a P ≤ 0.05, b P ≤ 0.01, c P ≤ 0.001. EZH2: Enhancer of zeste homolog 2; BSP: Bone sialoprotein; DSPP: Dentin sialophosphoprotein; <t>OCN:</t> Osteocalcin.
    Primary Antibodies Against Osteocalcin Ocn, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against osteocalcin ocn/product/Bioss
    Average 94 stars, based on 1 article reviews
    primary antibodies against osteocalcin ocn - by Bioz Stars, 2026-05
    94/100 stars
      Buy from Supplier

    86
    Servicebio Inc primary antibodies against osteocalcin
    Knockdown of enhancer of zeste homolog 2 inhibits steo/dentinogenic differentiation potential of human apical papillary stem cells. A: Quantitative polymerase chain reaction showed that the expression of enhancer of zeste homolog 2 (EZH2) was inhibited in human apical papillary stem cells (hSCAPs); B: Western blot analysis confirmed the knockdown of EZH2 in hSCAPs; C: Knockdown of EZH2 decreased alkaline phosphatase activity in hSCAPs; D and E: Alizarin red staining and quantitative calcium analysis demonstrated that knockdown of EZH2 inhibited mineralization in hSCAPs; F-H: Quantitative polymerase chain reaction showed that knockdown of EZH2 downregulated mRNA expression levels of bone sialoprotein (F), dentin sialophosphoprotein (G), and <t>osteocalcin</t> (H) in hSCAPs. GAPDH and ACTB was used as the internal controls. Data are presented as the mean ± SD ( n = 3). Statistical analysis was performed using Student’s t -test. a P ≤ 0.05, b P ≤ 0.01, c P ≤ 0.001. EZH2: Enhancer of zeste homolog 2; BSP: Bone sialoprotein; DSPP: Dentin sialophosphoprotein; <t>OCN:</t> Osteocalcin.
    Primary Antibodies Against Osteocalcin, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against osteocalcin/product/Servicebio Inc
    Average 86 stars, based on 1 article reviews
    primary antibodies against osteocalcin - by Bioz Stars, 2026-05
    86/100 stars
      Buy from Supplier

    90
    Servicebio Inc primary antibodies against osteocalcin (ocn)
    Abbreviations: AgÅPs: Ångstrom-scale silver particles; <t>OCN:</t> <t>Osteocalcin;</t> TRAP: Tartrate resistant acid phosphatase.
    Primary Antibodies Against Osteocalcin (Ocn), supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against osteocalcin (ocn)/product/Servicebio Inc
    Average 90 stars, based on 1 article reviews
    primary antibodies against osteocalcin (ocn) - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    90
    Wanleibio primary antibodies against osteocalcin (ocn) wlh4378
    Abbreviations: AgÅPs: Ångstrom-scale silver particles; <t>OCN:</t> <t>Osteocalcin;</t> TRAP: Tartrate resistant acid phosphatase.
    Primary Antibodies Against Osteocalcin (Ocn) Wlh4378, supplied by Wanleibio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against osteocalcin (ocn) wlh4378/product/Wanleibio
    Average 90 stars, based on 1 article reviews
    primary antibodies against osteocalcin (ocn) wlh4378 - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    90
    Affinity Biosciences primary antibodies against osteocalcin (ocn)
    Abbreviations: AgÅPs: Ångstrom-scale silver particles; <t>OCN:</t> <t>Osteocalcin;</t> TRAP: Tartrate resistant acid phosphatase.
    Primary Antibodies Against Osteocalcin (Ocn), supplied by Affinity Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against osteocalcin (ocn)/product/Affinity Biosciences
    Average 90 stars, based on 1 article reviews
    primary antibodies against osteocalcin (ocn) - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    90
    Servicebio Inc primary antibodies against osteocalcin (ocn, 1:200, gb11233, servicebio, wuhan, china)
    Abbreviations: AgÅPs: Ångstrom-scale silver particles; <t>OCN:</t> <t>Osteocalcin;</t> TRAP: Tartrate resistant acid phosphatase.
    Primary Antibodies Against Osteocalcin (Ocn, 1:200, Gb11233, Servicebio, Wuhan, China), supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against osteocalcin (ocn, 1:200, gb11233, servicebio, wuhan, china)/product/Servicebio Inc
    Average 90 stars, based on 1 article reviews
    primary antibodies against osteocalcin (ocn, 1:200, gb11233, servicebio, wuhan, china) - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    90
    ABclonal Biotechnology primary antibodies against osteocalcin
    Osteoblastic autophagy-related genes were upregulated in mouse OA model (A) Representative images of safranin O/fast green staining (top) and immunofluorescence of LC3 and <t>OCN,</t> DDIT3 and <t>OCN,</t> JUN and OCN, VEGFA and OCN (middle and bottom) co-immunostaining in the tibial subchondral bone of controls and DMM mice. Scale bar = 100 μm. (B) Quantitative analysis of the OARSI score of controls and DMM mice. n = 5 per group. (C–F) Quantitative analysis of the percentage of LC3 + , DDIT3 + , JUN + , and VEGFA + cells in OCN + cells of controls and DMM mice. n = 5 per group. (G) Representative images of safranin O/fast green staining (top) and immunofluorescence of LC3 and OCN, DDIT3 and OCN, JUN and OCN, VEGFA and OCN (middle and bottom) co-immunostaining in the tibial subchondral bone of mice aged 4 and 24 months. Scale bar = 100 μm. (H) Quantitative analysis of the OARSI score of mice aged 4 and 24 months. n = 6 per group. Scale bar = 100 μm. (I–L) Quantitative analysis of the percentage of LC3 + , DDIT3 + , JUN + , VEGFA + cells in OCN + cells of mice aged 4 and 24 months. n = 5 per group. (∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001; ns, p > 0.05).
    Primary Antibodies Against Osteocalcin, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against osteocalcin/product/ABclonal Biotechnology
    Average 90 stars, based on 1 article reviews
    primary antibodies against osteocalcin - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    86
    Danaher Inc primary antibodies against osteocalcin
    Osteoblastic autophagy-related genes were upregulated in mouse OA model (A) Representative images of safranin O/fast green staining (top) and immunofluorescence of LC3 and <t>OCN,</t> DDIT3 and <t>OCN,</t> JUN and OCN, VEGFA and OCN (middle and bottom) co-immunostaining in the tibial subchondral bone of controls and DMM mice. Scale bar = 100 μm. (B) Quantitative analysis of the OARSI score of controls and DMM mice. n = 5 per group. (C–F) Quantitative analysis of the percentage of LC3 + , DDIT3 + , JUN + , and VEGFA + cells in OCN + cells of controls and DMM mice. n = 5 per group. (G) Representative images of safranin O/fast green staining (top) and immunofluorescence of LC3 and OCN, DDIT3 and OCN, JUN and OCN, VEGFA and OCN (middle and bottom) co-immunostaining in the tibial subchondral bone of mice aged 4 and 24 months. Scale bar = 100 μm. (H) Quantitative analysis of the OARSI score of mice aged 4 and 24 months. n = 6 per group. Scale bar = 100 μm. (I–L) Quantitative analysis of the percentage of LC3 + , DDIT3 + , JUN + , VEGFA + cells in OCN + cells of mice aged 4 and 24 months. n = 5 per group. (∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001; ns, p > 0.05).
    Primary Antibodies Against Osteocalcin, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against osteocalcin/product/Danaher Inc
    Average 86 stars, based on 1 article reviews
    primary antibodies against osteocalcin - by Bioz Stars, 2026-05
    86/100 stars
      Buy from Supplier

    96
    Santa Cruz Biotechnology primary antibodies against osteocalcin
    Osteoblastic autophagy-related genes were upregulated in mouse OA model (A) Representative images of safranin O/fast green staining (top) and immunofluorescence of LC3 and <t>OCN,</t> DDIT3 and <t>OCN,</t> JUN and OCN, VEGFA and OCN (middle and bottom) co-immunostaining in the tibial subchondral bone of controls and DMM mice. Scale bar = 100 μm. (B) Quantitative analysis of the OARSI score of controls and DMM mice. n = 5 per group. (C–F) Quantitative analysis of the percentage of LC3 + , DDIT3 + , JUN + , and VEGFA + cells in OCN + cells of controls and DMM mice. n = 5 per group. (G) Representative images of safranin O/fast green staining (top) and immunofluorescence of LC3 and OCN, DDIT3 and OCN, JUN and OCN, VEGFA and OCN (middle and bottom) co-immunostaining in the tibial subchondral bone of mice aged 4 and 24 months. Scale bar = 100 μm. (H) Quantitative analysis of the OARSI score of mice aged 4 and 24 months. n = 6 per group. Scale bar = 100 μm. (I–L) Quantitative analysis of the percentage of LC3 + , DDIT3 + , JUN + , VEGFA + cells in OCN + cells of mice aged 4 and 24 months. n = 5 per group. (∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001; ns, p > 0.05).
    Primary Antibodies Against Osteocalcin, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against osteocalcin/product/Santa Cruz Biotechnology
    Average 96 stars, based on 1 article reviews
    primary antibodies against osteocalcin - by Bioz Stars, 2026-05
    96/100 stars
      Buy from Supplier

    Image Search Results


    Knockdown of enhancer of zeste homolog 2 inhibits steo/dentinogenic differentiation potential of human apical papillary stem cells. A: Quantitative polymerase chain reaction showed that the expression of enhancer of zeste homolog 2 (EZH2) was inhibited in human apical papillary stem cells (hSCAPs); B: Western blot analysis confirmed the knockdown of EZH2 in hSCAPs; C: Knockdown of EZH2 decreased alkaline phosphatase activity in hSCAPs; D and E: Alizarin red staining and quantitative calcium analysis demonstrated that knockdown of EZH2 inhibited mineralization in hSCAPs; F-H: Quantitative polymerase chain reaction showed that knockdown of EZH2 downregulated mRNA expression levels of bone sialoprotein (F), dentin sialophosphoprotein (G), and osteocalcin (H) in hSCAPs. GAPDH and ACTB was used as the internal controls. Data are presented as the mean ± SD ( n = 3). Statistical analysis was performed using Student’s t -test. a P ≤ 0.05, b P ≤ 0.01, c P ≤ 0.001. EZH2: Enhancer of zeste homolog 2; BSP: Bone sialoprotein; DSPP: Dentin sialophosphoprotein; OCN: Osteocalcin.

    Journal: World Journal of Stem Cells

    Article Title: EZH2, via an association with KDM2B, modulates osteogenic differentiation of root apical papillary stem cells

    doi: 10.4252/wjsc.v17.i4.103482

    Figure Lengend Snippet: Knockdown of enhancer of zeste homolog 2 inhibits steo/dentinogenic differentiation potential of human apical papillary stem cells. A: Quantitative polymerase chain reaction showed that the expression of enhancer of zeste homolog 2 (EZH2) was inhibited in human apical papillary stem cells (hSCAPs); B: Western blot analysis confirmed the knockdown of EZH2 in hSCAPs; C: Knockdown of EZH2 decreased alkaline phosphatase activity in hSCAPs; D and E: Alizarin red staining and quantitative calcium analysis demonstrated that knockdown of EZH2 inhibited mineralization in hSCAPs; F-H: Quantitative polymerase chain reaction showed that knockdown of EZH2 downregulated mRNA expression levels of bone sialoprotein (F), dentin sialophosphoprotein (G), and osteocalcin (H) in hSCAPs. GAPDH and ACTB was used as the internal controls. Data are presented as the mean ± SD ( n = 3). Statistical analysis was performed using Student’s t -test. a P ≤ 0.05, b P ≤ 0.01, c P ≤ 0.001. EZH2: Enhancer of zeste homolog 2; BSP: Bone sialoprotein; DSPP: Dentin sialophosphoprotein; OCN: Osteocalcin.

    Article Snippet: Immunohistochemical analysis followed established protocols[ ] using primary antibodies against osteocalcin (OCN) (Bioss bs-4917R) and DSPP (Bioss bs10316R).

    Techniques: Knockdown, Real-time Polymerase Chain Reaction, Expressing, Western Blot, Activity Assay, Staining

    Overexpression of enhancer of zeste homolog 2 enhances osteo/dentinogenic differentiation potential of human apical papillary stem cells. A: Quantitative polymerase chain reaction showed that enhancer of zeste homolog 2 (EZH2) was overexpressed in human apical papillary stem cells (hSCAPs); B: Western blot analysis confirmed overexpression of EZH2 in hSCAPs; C: Overexpression of EZH2 increased alkaline phosphatase activity in hSCAPs; D and E: Alizarin red staining and quantitative calcium analysis results demonstrated that overexpression of EZH2 enhanced mineralization in hSCAPs; F-H: Quantitative polymerase chain reaction showed that overexpression of EZH2 upregulated mRNA expression levels of bone sialoprotein (F), dentin sialophosphoprotein (G), and osteocalcin (H) in hSCAPs; I: Hematoxylin-eosin staining and quantitative measurement showed that overexpression of EZH2 promoted bone/dentin-like tissue formation. Scale bar = 100 μm (B: Bone/dentin-like tissues; HA: Hydroxyapatite tricalcium carrier; CT: Connective tissue); J: Immunohistochemical staining and quantitative analysis of dentin sialophosphoprotein and bone sialoprotein. GAPDH and ACTB were used as the internal controls. Data are presented as the mean ± SD ( n = 3). Statistical analysis was performed using Student’s t -test. a P ≤ 0.05, b P ≤ 0.01, c P ≤ 0.001. EZH2: Enhancer of zeste homolog 2; BSP: Bone sialoprotein; DSPP: Dentin sialophosphoprotein; OCN: Osteocalcin.

    Journal: World Journal of Stem Cells

    Article Title: EZH2, via an association with KDM2B, modulates osteogenic differentiation of root apical papillary stem cells

    doi: 10.4252/wjsc.v17.i4.103482

    Figure Lengend Snippet: Overexpression of enhancer of zeste homolog 2 enhances osteo/dentinogenic differentiation potential of human apical papillary stem cells. A: Quantitative polymerase chain reaction showed that enhancer of zeste homolog 2 (EZH2) was overexpressed in human apical papillary stem cells (hSCAPs); B: Western blot analysis confirmed overexpression of EZH2 in hSCAPs; C: Overexpression of EZH2 increased alkaline phosphatase activity in hSCAPs; D and E: Alizarin red staining and quantitative calcium analysis results demonstrated that overexpression of EZH2 enhanced mineralization in hSCAPs; F-H: Quantitative polymerase chain reaction showed that overexpression of EZH2 upregulated mRNA expression levels of bone sialoprotein (F), dentin sialophosphoprotein (G), and osteocalcin (H) in hSCAPs; I: Hematoxylin-eosin staining and quantitative measurement showed that overexpression of EZH2 promoted bone/dentin-like tissue formation. Scale bar = 100 μm (B: Bone/dentin-like tissues; HA: Hydroxyapatite tricalcium carrier; CT: Connective tissue); J: Immunohistochemical staining and quantitative analysis of dentin sialophosphoprotein and bone sialoprotein. GAPDH and ACTB were used as the internal controls. Data are presented as the mean ± SD ( n = 3). Statistical analysis was performed using Student’s t -test. a P ≤ 0.05, b P ≤ 0.01, c P ≤ 0.001. EZH2: Enhancer of zeste homolog 2; BSP: Bone sialoprotein; DSPP: Dentin sialophosphoprotein; OCN: Osteocalcin.

    Article Snippet: Immunohistochemical analysis followed established protocols[ ] using primary antibodies against osteocalcin (OCN) (Bioss bs-4917R) and DSPP (Bioss bs10316R).

    Techniques: Over Expression, Real-time Polymerase Chain Reaction, Western Blot, Activity Assay, Staining, Expressing, Immunohistochemical staining

    Abbreviations: AgÅPs: Ångstrom-scale silver particles; OCN: Osteocalcin; TRAP: Tartrate resistant acid phosphatase.

    Journal: Biomaterials Translational

    Article Title: Ångstrom-scale silver particle-infused hydrogels eliminate orthopedic implant infections and support fracture healing

    doi: 10.12336/biomatertransl.2025.01.007

    Figure Lengend Snippet: Abbreviations: AgÅPs: Ångstrom-scale silver particles; OCN: Osteocalcin; TRAP: Tartrate resistant acid phosphatase.

    Article Snippet: Immunohistochemical staining was performed using primary antibodies against osteocalcin (OCN) (Cat no.: GB11233, Servicebio, China) with a dilution of 1:300, tumor necrosis factor-alpha (TNF-α) (Cat no.: GB11188, Servicebio, China) with a dilution of 1:800, and interleukin-1 beta (IL-1β) (Cat no.: GB11113, Servicebio, China) with a dilution of 1:400.

    Techniques:

    Note: Statistical significance determined at * p < 0.05 and ** p < 0.01. Abbreviations: AgÅPs: Ångstrom-scale silver particles; E. coli: Escherichia coli ; Gel: Hydrogel; IM: Induced medium ; OCN: Osteocalcin; TRAP: Tartrate resistant acid phosphatase.

    Journal: Biomaterials Translational

    Article Title: Ångstrom-scale silver particle-infused hydrogels eliminate orthopedic implant infections and support fracture healing

    doi: 10.12336/biomatertransl.2025.01.007

    Figure Lengend Snippet: Note: Statistical significance determined at * p < 0.05 and ** p < 0.01. Abbreviations: AgÅPs: Ångstrom-scale silver particles; E. coli: Escherichia coli ; Gel: Hydrogel; IM: Induced medium ; OCN: Osteocalcin; TRAP: Tartrate resistant acid phosphatase.

    Article Snippet: Immunohistochemical staining was performed using primary antibodies against osteocalcin (OCN) (Cat no.: GB11233, Servicebio, China) with a dilution of 1:300, tumor necrosis factor-alpha (TNF-α) (Cat no.: GB11188, Servicebio, China) with a dilution of 1:800, and interleukin-1 beta (IL-1β) (Cat no.: GB11113, Servicebio, China) with a dilution of 1:400.

    Techniques:

    Osteoblastic autophagy-related genes were upregulated in mouse OA model (A) Representative images of safranin O/fast green staining (top) and immunofluorescence of LC3 and OCN, DDIT3 and OCN, JUN and OCN, VEGFA and OCN (middle and bottom) co-immunostaining in the tibial subchondral bone of controls and DMM mice. Scale bar = 100 μm. (B) Quantitative analysis of the OARSI score of controls and DMM mice. n = 5 per group. (C–F) Quantitative analysis of the percentage of LC3 + , DDIT3 + , JUN + , and VEGFA + cells in OCN + cells of controls and DMM mice. n = 5 per group. (G) Representative images of safranin O/fast green staining (top) and immunofluorescence of LC3 and OCN, DDIT3 and OCN, JUN and OCN, VEGFA and OCN (middle and bottom) co-immunostaining in the tibial subchondral bone of mice aged 4 and 24 months. Scale bar = 100 μm. (H) Quantitative analysis of the OARSI score of mice aged 4 and 24 months. n = 6 per group. Scale bar = 100 μm. (I–L) Quantitative analysis of the percentage of LC3 + , DDIT3 + , JUN + , VEGFA + cells in OCN + cells of mice aged 4 and 24 months. n = 5 per group. (∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001; ns, p > 0.05).

    Journal: iScience

    Article Title: Identification of osteoblastic autophagy-related genes for predicting diagnostic markers in osteoarthritis

    doi: 10.1016/j.isci.2024.110130

    Figure Lengend Snippet: Osteoblastic autophagy-related genes were upregulated in mouse OA model (A) Representative images of safranin O/fast green staining (top) and immunofluorescence of LC3 and OCN, DDIT3 and OCN, JUN and OCN, VEGFA and OCN (middle and bottom) co-immunostaining in the tibial subchondral bone of controls and DMM mice. Scale bar = 100 μm. (B) Quantitative analysis of the OARSI score of controls and DMM mice. n = 5 per group. (C–F) Quantitative analysis of the percentage of LC3 + , DDIT3 + , JUN + , and VEGFA + cells in OCN + cells of controls and DMM mice. n = 5 per group. (G) Representative images of safranin O/fast green staining (top) and immunofluorescence of LC3 and OCN, DDIT3 and OCN, JUN and OCN, VEGFA and OCN (middle and bottom) co-immunostaining in the tibial subchondral bone of mice aged 4 and 24 months. Scale bar = 100 μm. (H) Quantitative analysis of the OARSI score of mice aged 4 and 24 months. n = 6 per group. Scale bar = 100 μm. (I–L) Quantitative analysis of the percentage of LC3 + , DDIT3 + , JUN + , VEGFA + cells in OCN + cells of mice aged 4 and 24 months. n = 5 per group. (∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001; ns, p > 0.05).

    Article Snippet: Blots were probed with primary antibodies against JUN (cat#24909-1-AP, Proteintech, Wuhan, China), DDIT3 (cat#15204-1-AP, Proteintech, Wuhan, China), VEGFA (cat#19003-1-AP, Proteintech, Wuhan, China), LC3 (cat#14600-1-AP, Proteintech, Wuhan, China), Collagen 1a (COL1A1, cat#ab255809, Abcam, Cambridge, MA, USA), RUNX2 (cat#12556, Cell Signaling Technology, USA), Osteocalcin (OCN, cat#A20800, ABclonal, Wuhan, China), GAPDH (cat#60004-1-Ig, Proteintech, Wuhan, China), and immunoreactive proteins were revealed using an FDbio-Dura ECL Kit (cat#FD8020, Fudebio, Hangzhou, China).

    Techniques: Staining, Immunofluorescence, Immunostaining

    Osteoblastic autophagy-related genes were upregulated in OA patients (A) Representative images of safranin O/fast green staining (top) and immunofluorescence of LC3 and OCN, DDIT3 and OCN, JUN and OCN, VEGFA and OCN (middle and bottom) co-immunostaining in the tibial subchondral bone of OA patients. Scale bar = 100 μm. (B) Schematic diagram of tibial plateau tissue: in dotted line is the medial, corresponding to the Late-OA(OA group), and the opposite side is the lateral side which as the Early-OA(control group). (C) Quantitative analysis of the OARSI score of early-OA and late-OA. n = 5 per group. (D, E, F and G) Quantitative analysis of the percentage of LC3 + , DDIT3 + , JUN + , and VEGFA + cells in OCN + cells of early-OA and late-OA. n = 5 per group. (H) Western blot analysis the expression of JUN, DDIT3, VEGFA, LC3, COL1A1, RUNX2, and OCN in knee subchondral bone of OA. (I) Quantification of the expression of JUN, DDIT3, VEGFA, LC3, COL1A1, RUNX2, and OCN in knee subchondral bone of OA. (∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001; ns, p > 0.05).

    Journal: iScience

    Article Title: Identification of osteoblastic autophagy-related genes for predicting diagnostic markers in osteoarthritis

    doi: 10.1016/j.isci.2024.110130

    Figure Lengend Snippet: Osteoblastic autophagy-related genes were upregulated in OA patients (A) Representative images of safranin O/fast green staining (top) and immunofluorescence of LC3 and OCN, DDIT3 and OCN, JUN and OCN, VEGFA and OCN (middle and bottom) co-immunostaining in the tibial subchondral bone of OA patients. Scale bar = 100 μm. (B) Schematic diagram of tibial plateau tissue: in dotted line is the medial, corresponding to the Late-OA(OA group), and the opposite side is the lateral side which as the Early-OA(control group). (C) Quantitative analysis of the OARSI score of early-OA and late-OA. n = 5 per group. (D, E, F and G) Quantitative analysis of the percentage of LC3 + , DDIT3 + , JUN + , and VEGFA + cells in OCN + cells of early-OA and late-OA. n = 5 per group. (H) Western blot analysis the expression of JUN, DDIT3, VEGFA, LC3, COL1A1, RUNX2, and OCN in knee subchondral bone of OA. (I) Quantification of the expression of JUN, DDIT3, VEGFA, LC3, COL1A1, RUNX2, and OCN in knee subchondral bone of OA. (∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001; ns, p > 0.05).

    Article Snippet: Blots were probed with primary antibodies against JUN (cat#24909-1-AP, Proteintech, Wuhan, China), DDIT3 (cat#15204-1-AP, Proteintech, Wuhan, China), VEGFA (cat#19003-1-AP, Proteintech, Wuhan, China), LC3 (cat#14600-1-AP, Proteintech, Wuhan, China), Collagen 1a (COL1A1, cat#ab255809, Abcam, Cambridge, MA, USA), RUNX2 (cat#12556, Cell Signaling Technology, USA), Osteocalcin (OCN, cat#A20800, ABclonal, Wuhan, China), GAPDH (cat#60004-1-Ig, Proteintech, Wuhan, China), and immunoreactive proteins were revealed using an FDbio-Dura ECL Kit (cat#FD8020, Fudebio, Hangzhou, China).

    Techniques: Staining, Immunofluorescence, Immunostaining, Control, Western Blot, Expressing

    Journal: iScience

    Article Title: Identification of osteoblastic autophagy-related genes for predicting diagnostic markers in osteoarthritis

    doi: 10.1016/j.isci.2024.110130

    Figure Lengend Snippet:

    Article Snippet: Blots were probed with primary antibodies against JUN (cat#24909-1-AP, Proteintech, Wuhan, China), DDIT3 (cat#15204-1-AP, Proteintech, Wuhan, China), VEGFA (cat#19003-1-AP, Proteintech, Wuhan, China), LC3 (cat#14600-1-AP, Proteintech, Wuhan, China), Collagen 1a (COL1A1, cat#ab255809, Abcam, Cambridge, MA, USA), RUNX2 (cat#12556, Cell Signaling Technology, USA), Osteocalcin (OCN, cat#A20800, ABclonal, Wuhan, China), GAPDH (cat#60004-1-Ig, Proteintech, Wuhan, China), and immunoreactive proteins were revealed using an FDbio-Dura ECL Kit (cat#FD8020, Fudebio, Hangzhou, China).

    Techniques: Software